Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Stock Information for Aclaris Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aclaris Therapeutics Inc.

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
Aclaris Therapeutics to Participate in Two September Healthcare Conferences
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.